Emma Walmsley Sells 148,525 Shares of GSK plc (LON:GSK) Stock
GSK plc (LON:GSK – Get Rating) insider Emma Walmsley sold 148,525 shares of the company’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,763 ($21.24), for a total transaction of £2,618,495.75 ($3,154,814.16).
Emma Walmsley also recently made the following trade(s):
- On Monday, July 4th, Emma Walmsley purchased 7 shares of GSK stock. The shares were bought at an average cost of GBX 1,799 ($21.67) per share, for a total transaction of £125.93 ($151.72).
GSK Price Performance
Shares of GSK stock traded down GBX 15.60 ($0.19) during midday trading on Friday, reaching GBX 1,727.40 ($20.81). 2,973,824 shares of the company were exchanged, compared to its average volume of 8,817,376. GSK plc has a 12 month low of GBX 1,362.80 ($16.42) and a 12 month high of GBX 1,824.40 ($21.98). The company has a market cap of £87.82 billion and a P/E ratio of 1,369.52. The company’s 50 day moving average price is GBX 1,734.52 and its two-hundred day moving average price is GBX 1,686.59. The company has a debt-to-equity ratio of 147.36, a quick ratio of 0.94 and a current ratio of 1.19.
GSK Increases Dividend
The firm also recently disclosed a dividend, which will be paid on Thursday, October 6th. Stockholders of record on Thursday, August 18th will be paid a GBX 16.25 ($0.20) dividend. The ex-dividend date of this dividend is Thursday, August 18th. This represents a dividend yield of 0.93%. This is a boost from GSK’s previous dividend of $14.00. GSK’s payout ratio is currently 63.49%.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. Citigroup reissued a “neutral” rating and issued a GBX 1,975 ($23.80) target price on shares of GSK in a research note on Thursday, July 21st. UBS Group set a GBX 1,850 ($22.29) price target on shares of GSK in a report on Thursday. Barclays reaffirmed an “equal weight” rating and set a GBX 1,800 ($21.69) price target on shares of GSK in a report on Monday, July 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,750 ($21.08) price target on shares of GSK in a report on Tuesday. Finally, Credit Suisse Group set a GBX 1,630 ($19.64) price target on shares of GSK in a report on Thursday. One analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of GBX 1,826.67 ($22.01).
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider GSK, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and GSK wasn’t on the list.
While GSK currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.